The FDA approves remibrutinib for symptomatic dermographism, the first such therapy, extending an oral BTK inhibitor label via the Phase III RemIND trial.
News|Articles|April 24, 2020
Swiss Biotech Sector is Experiencing Continued Growth, Notes Sector Report
Author(s)Pharmaceutical Technology Editors
A report into the Swiss biotech sector has shown that there is continued growth in the sector, which has received investments from public and private companies worth CHF 1.2 billion (US$1.2 billion).
Advertisement
A report into the Swiss biotech sector, launched on April 21, 2020 by the Swiss Biotech Association, has shown that there is continued growth in the sector, which has received investments from public and private companies worth CHF 1.2 billion (US$1.2 billion).
Other key findings of the report include a boost in revenues for the sector, which reached CHF 4.8 billion (US$4.9 billion) in 2019, and the emergence of new strengths, with major companies expanding production capacity. Additionally, the report highlighted the favorable and comprehensive life sciences ecosystem that exists in Switzerland, which has contributed to making it an attractive funding environment.
“The Swiss Biotech Report 2020 shows that Switzerland has a comprehensive life sciences ecosystem-from research to manufacturing-that Swiss biotech companies can rely on and thus continue to thrive,” said Michael Altorfer, CEO Swiss Biotech Association, in an April 21, 2020 press release. “Economically, life sciences are a major pillar of the Swiss economy, accounting for 40% of exports with a truly global reach. The report also shows that the sector is not standing still with growth in new areas and a rise in international collaborations and investments. However, I would caution that more work is needed to attract large institutional investors who shy away from this sector despite its proven and attractive track record to deliver above average return on investment.”
Source:
Advertisement
Related to this article
The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Advertisement
Advertisement